开云app官网登录入口网页版-官方正版

#MPE#

26篇内容 | 1215人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016666, encodeId=c66c2016666b8, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=最新进展 | N末端B型利钠肽前体和高敏心肌肌钙蛋白T在EMPEROR-Preserved试验中的预后意义, objectType=article, longId=738817, objectId=22e4e38817da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22e4e38817da, replyNumber=0, likeNumber=85, createdTime=2023-08-20, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22e4e38817da, moduleTitle=最新进展 | N末端B型利钠肽前体和高敏心肌肌钙蛋白T在EMPEROR-Preserved试验中的预后意义, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22e4e38817da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016665, encodeId=acff2016665e6, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=71, createdTime=2022-08-02, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016664, encodeId=042c2016664bc, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, objectType=article, longId=725499, objectId=bec0e25499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec0e25499db, replyNumber=0, likeNumber=74, createdTime=2022-12-18, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec0e25499db, moduleTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bec0e25499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016663, encodeId=a94c201666317, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Eur Respir J ：COMPERA 2.0:改良的肺动脉高压四层风险评估模型, objectType=article, longId=219943, objectId=76b721994357, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76b721994357, replyNumber=0, likeNumber=105, createdTime=2022-06-17, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76b721994357, moduleTitle=Eur Respir J ：COMPERA 2.0:改良的肺动脉高压四层风险评估模型, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=76b721994357)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016662, encodeId=bc4c2016662db, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果, objectType=article, longId=218499, objectId=caf221849998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=caf221849998, replyNumber=0, likeNumber=59, createdTime=2022-06-15, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=caf221849998, moduleTitle=ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=caf221849998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016660, encodeId=4b7c201666093, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=66, createdTime=2022-01-08, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016661, encodeId=fb7120166618c, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=CHEST：慢性阻塞性肺病患者的肺动脉高压--COMPERA研究结果公布, objectType=article, longId=217933, objectId=a73721e93388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a73721e93388, replyNumber=0, likeNumber=57, createdTime=2022-03-31, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a73721e93388, moduleTitle=CHEST：慢性阻塞性肺病患者的肺动脉高压--COMPERA研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a73721e93388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016659, encodeId=ce6b2016659df, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=75, createdTime=2022-04-27, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016658, encodeId=b5dc2016658aa, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Imperial College London：中国出国新冠病例有2/3未被发现, objectType=article, longId=189258, objectId=026818925850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=026818925850, replyNumber=0, likeNumber=71, createdTime=2020-04-12, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=026818925850, moduleTitle=Imperial College London：中国出国新冠病例有2/3未被发现, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=026818925850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016656, encodeId=389e20166564b, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势, objectType=article, longId=187112, objectId=2e9d18e11225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e9d18e11225, replyNumber=0, likeNumber=63, createdTime=2020-06-25, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e9d18e11225, moduleTitle=Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e9d18e11225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016657, encodeId=6c09201665e02, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高, objectType=article, longId=188043, objectId=08ea1880437a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ea1880437a, replyNumber=0, likeNumber=82, createdTime=2020-04-06, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ea1880437a, moduleTitle=JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08ea1880437a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016654, encodeId=c8ab201665446, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Stempeutics干细胞药物Stempeucel治疗严重肢体缺血，喜获USPTO授予的美国专利, objectType=article, longId=182363, objectId=16e418236379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16e418236379, replyNumber=0, likeNumber=59, createdTime=2020-06-06, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16e418236379, moduleTitle=Stempeutics干细胞药物Stempeucel治疗严重肢体缺血，喜获USPTO授予的美国专利, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=16e418236379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016653, encodeId=8f00201665391, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复, objectType=article, longId=180495, objectId=350f180495e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=350f180495e8, replyNumber=0, likeNumber=62, createdTime=2020-02-01, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=350f180495e8, moduleTitle=Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=350f180495e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016655, encodeId=dddf20166558b, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=JAMA：Bempedoic Acid用于他丁类效果不佳的高血脂患者, objectType=article, longId=182960, objectId=4a31182960f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a31182960f8, replyNumber=0, likeNumber=68, createdTime=2020-05-14, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a31182960f8, moduleTitle=JAMA：Bempedoic Acid用于他丁类效果不佳的高血脂患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4a31182960f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016650, encodeId=c5162016650e5, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=NEJM：新型降脂药物bempedoic acid安全有效的降低LDL胆固醇水平, objectType=article, longId=162567, objectId=61b816256efb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61b816256efb, replyNumber=0, likeNumber=78, createdTime=2020-01-04, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61b816256efb, moduleTitle=NEJM：新型降脂药物bempedoic acid安全有效的降低LDL胆固醇水平, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=61b816256efb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016648, encodeId=30dc2016648fc, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, objectType=article, longId=160531, objectId=d64716053136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64716053136, replyNumber=0, likeNumber=64, createdTime=2019-11-03, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64716053136, moduleTitle=Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d64716053136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016652, encodeId=147520166529d, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=74, createdTime=2019-12-12, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016649, encodeId=f0e6201664919, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=NEJM：Bempedoic acid降低LDL胆固醇的安全性和疗效, objectType=article, longId=162318, objectId=057a16231874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=057a16231874, replyNumber=0, likeNumber=54, createdTime=2019-09-22, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=057a16231874, moduleTitle=NEJM：Bempedoic acid降低LDL胆固醇的安全性和疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=057a16231874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016651, encodeId=3d9d201665185, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=刘颖斌教授：胰头癌全系膜切除（TMpE）可提高R0切除率，改善预后, objectType=article, longId=163143, objectId=f63616314379, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f63616314379, replyNumber=0, likeNumber=60, createdTime=2020-02-06, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f63616314379, moduleTitle=刘颖斌教授：胰头癌全系膜切除（TMpE）可提高R0切除率，改善预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f63616314379)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016647, encodeId=93c2201664e0b, content=<a href='/topic/show?id=90e9121e19f' target=_blank style='color:#2F92EE;'>#MPE#</a>, objectTitle=Cell Physiol Biochem：BMPER通过促进骨髓间充质干细胞的成骨-血管生成偶联过程增强骨形成, objectType=article, longId=132350, objectId=a10a1323508e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a10a1323508e, replyNumber=0, likeNumber=103, createdTime=2018-12-25, rootId=0, userName=soongzhihua, userId=7f52347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a10a1323508e, moduleTitle=Cell Physiol Biochem：BMPER通过促进骨髓间充质干细胞的成骨-血管生成偶联过程增强骨形成, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a10a1323508e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

MPE

2020-05-29

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

最新进展 | N末端B型利钠肽前体和高敏心肌肌钙蛋白T在EMPEROR-Preserved试验中的预后意义

2023-08-20

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-08-02

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌

2022-12-18

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Eur Respir J ：COMPERA 2.0:改良的肺动脉高压四层风险评估模型

2022-06-17

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果

2022-06-15

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2022-01-08

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

CHEST：慢性阻塞性肺病患者的肺动脉高压--COMPERA研究结果公布

2022-03-31

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2022-04-27

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Imperial College London：中国出国新冠病例有2/3未被发现

2020-04-12

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势

2020-06-25

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高

2020-04-06

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Stempeutics干细胞药物Stempeucel治疗严重肢体缺血，喜获USPTO授予的美国专利

2020-06-06

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Biomed Res Int：mPEG-PCL-mPEG /羟基磷灰石复合支架可用于骨组织工程用于骨缺损的修复

2020-02-01

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

JAMA：Bempedoic Acid用于他丁类效果不佳的高血脂患者

2020-05-14

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

NEJM：新型降脂药物bempedoic acid安全有效的降低LDL胆固醇水平

2020-01-04

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Opdivo与bempegaldesleukin联合用于一线治疗尿路上皮癌的结果令人满意

2019-11-03

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2019-12-12

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

NEJM：Bempedoic acid降低LDL胆固醇的安全性和疗效

2019-09-22

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

刘颖斌教授：胰头癌全系膜切除（TMpE）可提高R0切除率，改善预后

2020-02-06

soongzhihua (审核中...)

前往app查看评论内容

#MPE#

Cell Physiol Biochem：BMPER通过促进骨髓间充质干细胞的成骨-血管生成偶联过程增强骨形成

2018-12-25

科室
- - 订阅+
  - 更多科室
工具
服务